knowledge -WSS

knowledge

author：explore 2025-09-06 04:50:46 - browse：7

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Search called off for baby washed away in Pennsylvania flash flood

leisure time

entertainment

WSS

In the gardens at Boston Children's Hospital, families find sanctuary

What it's like to live with paralysis for one psychologist

Roche’s Alnylam deal shows drug firms interested in heart drugs

What causes rare myocarditis in young men after Covid vaccines?

What it's like to live with paralysis for one psychologist

Medicare explains how it will choose drugs for negotiation

focus

knowledge

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Radiation, mainstay of cancer treatment, begins a fade

23andMe had bad news about my health. I wish a person had delivered it

Senate panel puts off hardest PBM reforms for another day

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why patients can’t get everything they want on drug pricing

Alkermes shareholders re

The haunting brain science of long Covid

At least 13 dead in Texas as scorching temps continue

The haunting brain science of long Covid

explore

Study finds new variant for Parkinson’s in African populations

Will the FTC rein in IQVIA's health data empire?

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

As pharma fights Medicare drug negotiation, hospitals, docs silent

Neuroscience startup Neumora files for IPO

What to watch for from Zogenix and Amicus clinical trials

leisure time

leisure time

entertainment

Wikipedia